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Abstract The aim of this study was to evaluate the clinical
symptoms, the otoneurological examinations, the treatment
and the clinical course of three patients suffering from
Cogan’s syndrome, a rare disease based on the clinical as-
sociation of a non-syphilitic interstitial keratitis with a
cochleo-vestibular deficit. This case series involved three
patients with follow up. The clinical course of the three
patients (aged 30, 48 and 49 years) with Cogan’s syn-
drome during a follow-up period of 2 to 6 years is reported.
All patients underwent complete otoneurological, ophthal-
mologic and rheumatologic examinations and were treated
with immunosuppressive therapy such as glucocorticoids
and cyclophosphamide in two and glucocorticoids and
methotrexate in one patient. Using immunosuppressive
therapy, ophthalmologic symptoms disappeared rapidly in
two patients. Hearing improved only in one and stabilized
in a second patient. One patient died after 6 years of treat-
ment because of complications of generalized vasculitis.
Early diagnosis and rapid initiation of a combined immuno-
suppressive therapy such as corticosteroids and cyclo-
phosphamide seem to be important in controlling the dis-
ease and avoiding persistent deafness. Whether systemic
complications and a fatal outcome also can be prevented
is still questionable.
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Introduction
Cogan’s syndrome was first defined as a clinical entity by
the ophthalmologist David Cogan in 1945 based on his
observations of four patients [1]. It is defined as the asso-
ciation of a non-syphilitic interstitial keratitis with a cochleo-
vestibular deficit. In general, the hearing loss is bilateral,
rapidly progressive and often combined with tinnitus, ver-
tigo, dizziness or ataxia. The term “atypical Cogan’s syn-
drome” refers to non-specific ocular inflammations such
as episcleritis, scleritis, iritis or uveitis, or to the delay of
occurrence of the cardinal symptoms for more than 2 years
[2, 3]. Cogan’s syndrome is rare and usually occurs in
adults between the 2nd and 4th decades [2, 4], but some
cases have also been reported in childhood [5]. In this ar-
ticle, we report the clinical observations and the course of
three patients, two of them suffering from a typical and
one from an atypical Cogan’s syndrome.
Subjects and methods
Patients
Between 1991 and 2001, three patients (two men aged 33 and 
49 years and one woman aged 48 years) with Cogan’s syndrome
were treated at the ENT Clinic of the University Hospital of Berne.
A complete otoneurological examination was performed, includ-
ing pure-tone audiometry (PTA), impedance audiometry with mea-
surements of reflex decay, brainstem-evoked auditory potentials
(BEAPs) and electronystagmography (ENG). All patients under-
went a full clinical ophthalmologic examination, including a biopsy
from the conjunctiva.
A chest X-ray, kidney ultrasonography and cerebral MRI were
performed to determine possible systemic organ involvement. Sys-
temic vasculitic components were researched using clinical and lab-
oratory examinations like C-reacting protein (CRP), erythrocyte
sedimentation rate (ESR), antinuclear antibody (ANA) and anti-
neutrophilic cytoplasmatic antibody assays (p-ANCA), rheuma-
toid factor and complement factors C1q, C3 and C4. Furthermore,
the patients underwent serological tests for various infectious agents
(treponema, borrelia, herpes simplex/varizella zoster, HIV, Ep-
stein-Barr virus, cytomegalovirus, mumps virus, flavivirus and Toxo-
plasma gondi).
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Ten days after a viral infection with fever and symptoms of a com-
mon cold, a 33-year-old man suffered from a rapidly progressive
bilateral hearing loss and tinnitus. He also complained of photo-
phobia, continuous tearing and sensation of an ocular foreign
body. The ophthalmologic examination demonstrated bilateral in-
terstitial keratitis (Fig. 1). Corneal biopsy showed no signs of vas-
culitis or deposits of immunoglobulins or complements. The oto-
neurological examination revealed a moderate to severe bilateral
sensorineural hearing loss with normal BEAP latencies at supra-
threshold levels on the left side as well as a bilateral peripheral
vestibular deficit with bilateral caloric areflexia as determined by
the ENG results (Fig. 2). Laboratory analysis showed an increased
ESR (30 mm/h), increased complement factors C3 [1.95 g/l (norm:
0.74–1.3 g/l)] and C4 [0.47 g/l (norm: 0.10–0.34 g/l)]. All serolog-
ical tests for neutrophic antigens were negative. Systemic organ in-
volvement was excluded by chest X-ray, kidney ultrasonography
and cerebral MRI.
After the diagnosis of typical Cogan’s syndrome was made,
treatment with corticoids was instituted, topically for ocular in-
flammation and systemic (2 mg/kg per day) for vestibulocochlear
symptoms. Under this treatment, fever and interstitial keratitis dis-
appeared rapidly within days. Hearing loss and equilibrium, how-
ever, became continuously worse.
Because the patient first declined a supplementary therapy with
cyclophosphamide, azathioprine 150 mg/day was started. When
hearing on the left side deteriorated further, the patient finally con-
sented to the therapy with cyclophosphamide, which was given in-
travenously at a dose of 1 g per session monthly for 6 months. This
treatment was tolerated well without any side effects. Clinically
and objectively documented by audiometric testing, hearing on the
right side became much better in the low frequencies and partially
improved and stabilized on the left side (Fig. 2). Dizziness practi-
cally disappeared after an intensive vestibular physiotherapy. At
the last visit, 30 months after the onset of symptoms, the patient
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Fig. 1 Ophthalmological picture of the interstitial keratitis of case 1
with corneal cell inclusions in the slit-lamp examination (typical
Cogan’s syndrome)
Fig. 2 Pure tone audiogram
(PTA) before and after treat-
ment
continued on a daily regimen of 5 mg oral prednisone; the hearing
threshold remained stable and the patient was fitted for hearing
aids on both sides. He no longer complained of symptoms, includ-
ing dizziness or ocular discomfort.
Case 2
A 48-year-old woman complained of progressive bilateral sen-
sorineural hearing loss and dizziness, associated with recurrent
fever and polyarthralgia. Seven weeks later, she developed a clini-
cally severe keratitis and conjunctivitis in the right eye; these
symptoms motivated the patient to consult a doctor for the first
time. The otoneurological examination revealed a bilateral sen-
sorineural hearing loss with normal BEAP latencies at suprathresh-
old levels and a left caloric hyporeflexia on ENG (Fig. 2). Labora-
tory analysis showed increased ESR (125 mm/h), CRP (98 mg/l)
and a strongly increased complement factor C3 (2.41 g/l). Serolog-
ical tests for viral antigens were negative.
Treatment with oral corticosteroids (100 mg, 75 mg and 50 mg
for 7 consecutive days each) was started 8 weeks after the onset of
the symptoms. Arthralgias, fever and the keratitis disappeared, but
the hearing threshold improved only a little. One month later, she
complained again of hearing loss and arthralgias. Therefore, cyclo-
phosphamide (1 g per month intravenously) was added to the cor-
ticoid treatment for the long term because of recurrent arthralgia
and fever. Despite this combined therapy, bilateral hearing loss
and ataxia basically remained unchanged and within 2 years the
patient developed cardiac vasculitis with a severe cardiac infarc-
tion and cerebral vasculitis with ischemia of the thalamus, clini-
cally manifested by a sensomotoric paresis. Cyclophosphamide
was replaced by methotrexate (20 mg per week). Nevertheless the
clinical evolution continued to deteriorate with the development of
a severe aortic valve insufficiency. Moreover, as side effects of
corticosteroid therapy, diabetes mellitus, osteoporosis and cataract
occurred. Six years after starting immunosuppressive treatment,
the patient died of cardiac failure.
Case 3
A 49-year-old man complained of a sudden bilateral hearing loss
within a few weeks, but without vertigo or dizziness. Nine months
later, the patient suffered from repeated fever episodes, arthralgia,
loss of weight and a severe bilateral nodular scleritis, resistant to a
2-month locally administered steroid therapy (Fig. 3). Because of
additional progressive hearing loss, an otoneurological examina-
tion was performed. This revealed a bilateral sensorineural hearing
loss in the high frequencies with normal BEAP latencies as well as
a unilateral peripheral vestibular deficit with a left caloric hypo-
reflexia (Fig. 2). Laboratory analysis showed an increased ESR 
(60 mm/h), CRP (70 mg/l) and complement factor C1q [65 ug/ml
(norm: <35 ug/m)]. All serological tests for neutrophic antigens
were negative. On echocardiography, the patient showed a mild
aortic valve insufficiency.
Only when the ocular symptoms (scleritis and episcleritis with
photophobia and pains) had appeared was the diagnosis of an atyp-
ical Cogan’s syndrome made and systemic corticosteroid treatment
(2 mg/kg per day) started. Under this treatment, hearing thresholds
improved markedly, but the episcleritis and scleritis became worse,
together with recurring fever. Because after 4 weeks increasing
doses of systemic corticosteroids had been ineffective, cyclophos-
phamide at a dose of 100 and later 150 mg/day was added. With
this treatment, the ocular manifestations disappeared within a 
few weeks. Therapy with cyclophosphamide was continued for 
12 months, whereas oral corticosteroids could be tapered off within
3 months to 5 mg. During an examination 3 years after the onset of
the first hearing symptoms, hearing thresholds remained stable and
the patient was fitted with hearing aids.
Discussion
The present study describes the clinical evolution and long-
term follow-up of three patients suffering from Cogan’s
syndrome. Although this syndrome has been known for more
than 50 years and more than 150 case reports have been
published, there are still no specific and accurate tests for
diagnosis [2, 6, 7], and with respect to treatment, many
questions remain unanswered. In our patients, elevated
ESR, CRP as well as some non-specific alterations of the
complement system were the only notable abnormal labo-
ratory parameters. These findings, often noticed in inflam-
matory processes, however, are non-specific.
Only when both cardinal symptoms (cochleovestibular
and eye disease) are present does the clinical diagnosis of
Cogan’s syndrome becomes obvious. The diagnostic main-
stay is to verify the presence of interstitial keratitis. How-
ever, prolonged prodromal phases or staggered occur-
rence of the cardinal symptoms may render the diagnosis
difficult, as demonstrated by case 3. In a retrospective study
of 98 patients originating from ten countries in Western
Europe, Majoor [8] redefined the typical and atypical
Cogan’s syndromes. He included obligatorily an interstitial
keratitis in addition to another significant inflammatory
eye lesion. According to the definition of Cody et al. [9]
and Haynes et al. [2], we considered that patient 3 might
have an atypical Cogan’s syndrome, despite the absence
of interstitial keratitis.
Hearing loss is usually bilateral and progressive and
leads to total deafness in 40–60% of reported cases [2, 4].
The course with hearing fluctuation, tinnitus and vertigo
attacks may resemble Meniere’s disease. Attacks of diz-
ziness are commonly severe and usually accompanied 
by ataxia, caused by the bilateral progressive peripheral
vestibular deficit. The initial symptoms are ophthalmo-
logical in 37% of typical Cogan’s syndrome and in 45%
of atypical Cogan’s syndrome. The cochleo-vestibular
symptoms present themselves initially in only about 30%
of the patients [8].
In addition, systemic symptoms like fever, headache,
arthralgias, myalgias and weight loss may occur. Known
47
Fig. 3 Ophthalmological picture of the episkleritis of case 3 (atyp-
ical Cogan’s syndrome)
systemic complications of Cogan’s syndrome are vasculi-
tis of the coronary, intestinal or cerebral vessels. Aortic
insufficiency in particular indicates a poor prognosis, as
illustrated by case 2 in our series. In approximately half of
the cases in the literature, systemic manifestations occur,
mostly associated with atypical Cogan’s syndrome [2, 4,
10]. Depending on the organ systems involved, mortality
is estimated at 10%.
The etiology of Cogan’s syndrome is still not com-
pletely understood. Based on the demonstration of anti-
bodies against inner ear and corneal tissue as well as
cell-mediated immune phenomena, there is evidence that
Cogan’s syndrome may be an autoimmune disease [11, 12,
13, 14]. However, it is not clear whether humoral or cel-
lular mechanisms induce the process and progression of
the disease. Although Arnold et al. demonstrated IgG and
IgA antibodies from sera of patients with Cogan’s syn-
drome directed against epithelial cells of healthy corneas
and against membranous labyrinth structure [11, 15], in-
filtration of lymphocytes and plasma cells in the cochlea
and general thickening of the membranous labyrinth have
been found, suggesting a cell-mediated response [2, 6].
The significance of the serum antibodies is not clear, since
they do not correlate well with the clinical course and the
activity of the disease [6]. Very recently, Lunardi et al.
[12] identified an immunodominant peptide in the sera of
patients suffering from Cogan’s syndrome. This Cogan
peptide shares homology with the cell-density-enhanced
protein tyrosine phosphatase-1 (DEP-1/CD148), which is
expressed on the sensory epithelia of the inner ear and on
endothelial cells. The IgG antibodies against this peptide,
purified from the patient’s sera, recognized autoantigens
and DEP-1/CD148 protein bound human cochlea.
These antibodies bound connexin 26 and were able to
induce the features of Cogan’s disease in mice. Our pa-
tients did not have tests for this specific peptide. A fore-
going viral infection, as observed in case 1, is reported in
40% of the patients with Cogan’s syndrome [2, 4, 10].
These observations suggested that an autoimmune process
could be initiated in some cases by a viral infection.
Lunardi et al. [12] found a homology between the Cogan
peptide and autoantigens such as SSA/Ro as well as the
reovirus III major core protein lambda 1. These findings
tend to confirm the hypothesis of an autoimmunological
mechanism induced by a previous viral infection.
The histopathological examinations of the temporal
bones of patients with Cogan’s syndrome show the typical
findings of endolymphatic hydrops. In addition, atrophy
of the hair cells and the supporting cells, focal and diffuse
proliferation of fibrous tissue and bone (“neo-osteogene-
sis”) as well as retrograde neuronal degeneration are also
observed [16, 17]. Based on MRI findings of inner ears of
patients suffering from Cogan’s syndrome, Majoor et al.
hypothesized that its physiopathology might be due to an
obstructive vasculitis [18].
Since the etiopathology is still not completely under-
stood, there is no agreement concerning the therapy regi-
men. Systemic corticosteroids are considered as the pri-
mary and standard treatment of Cogan’s syndrome [2, 10].
From the ophthalmological side, ocular symptoms usually
respond well even to topically applied corticosteroids [3,
19]. Atypical Cogan’s syndrome with panuveitis as well as
scleritis/episcleritis, however, tends to produce a chronic
course that may require a more aggressive systemic treat-
ment, as illustrated by case 3 with the atypical Cogan’s
syndrome [3]. In the literature, prednisone is recommended
at a dose of 2 mg/kg per day initially [2, 10]. In several
reports in which treatment with corticosteroids failed,
various immunosuppressants such as cyclophosphamide
(1–2 mg/kg per day), cyclosporin A (1–2 mg/kg per day)
[2, 5, 20] or methotrexate (7.5–10 mg per week) have been
introduced with favorable results [21, 22]. In our cases,
we primarily used cyclophosphamide, which previously has
been demonstrated to be effective in eradicating B-cell
clones producing autoantibodies in a variety of diseases [23].
Based on a study of 15 patients and a literature review
of 111 cases, Haynes suggested that treatment should be-
gin as early as possible, e.g., within the first 2 weeks after
the appearance of the cochleo-vestibular symptoms [2].
But even in cases with early treatment, hearing improve-
ments are variable and often only partial, as seen in case 1.
A long delay between the onset of symptoms and the
initiation of treatment can issue an irreversible atrophy
and degeneration of inner ear structures with the typical
picture of an endolymphatic hydrops in the advanced
stage of the disease. At this late stage with endolymphatic
hydrops, treatment can only improve hearing fluctuations
and attempt to inhibit further hearing loss. Furthermore,
current dosage of the systemic immunosuppressive ther-
apy seems not to be high enough, because concentrations
of corticosteroids in the perilymph and cerebrospinal fluid
are much lower than in the plasma [24]. High levels of
corticoids in the endo- and perilymph are very important
in treating inflammatory inner ear disorders, since the end
organs are bathed in these liquids [25]. Furthermore, the
endolymphatic sac is probably the source of the inner ear
immune response [15]. For this reason, local intratym-
panic corticosteroid applications have been used in differ-
ent studies with encouraging results [24, 25, 26]. How-
ever, the number of these cases is still too small to con-
firm the efficacy of this treatment.
Conclusions
Cogan’s syndrome should always be considered in pa-
tients presenting a progressive hearing loss associated with
ocular inflammations. According to the findings of this
study, early recognition of Cogan’s syndrome and rapid ini-
tiation of combined immunosuppressive therapy, such as
corticosteroids and cyclophosphamide, seem to be impor-
tant in preventing persistent deafness. Whether systemic
complications and a fatal outcome also can be prevented
still remains unanswered.
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